Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Inhibrx Inc.
INBX | US
15.50
USD-0.50
-3.13%
INBX | US
About Inhibrx Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
15.50
Open
15.84
High
15.93
Low
15.50
Inhibrx Inc. a clinical-stage biopharmaceutical company focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109 a tetravalent agonist of death receptor 5 which is in Phase 2 clinical trials to treat cancers such as chondrosarcoma mesothelioma and pancreatic adenocarcinoma; INBRX-105 a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101 an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106 a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio Inc. Bristol-Myers Squibb Company and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla California.
View LessINBX | US
Risk
35.2
Sharpe
-0.32
Luna's Score
52/100
Recommendation
Hold
Luna says (INBX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
37.1%1 month
35.2%3 months
59.5%6 months
54.2%Returns
Fundamental Ratios
PE
0.13
Fwd. PE
-
Price to book
1.07
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.01
Ent. to rev.
5.56
PEG
-
Other Fundamentals
EBITDA
-300.93M
MarketCap
224.38M
MarketCap(USD)
224.38M
Div. yield
-
Op. margin
-160.90K
Erngs. growth
-
Rev. growth
233.30
Ret. on equity
-2.03K
Short ratio
5.76
Short perc.
5.71
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
2.31
Range1M
2.35
Range3M
6.99
Volumes: Market Activity
Rel. volume
0.22
Price X volume
313.92K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.01 | 0.53 | Cheaper |
| Ent. to Revenue | 5.56 | 3,967.00 | Cheaper |
| PE Ratio | 0.13 | 41.03 | Cheaper |
| Price to Book | 1.07 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 59.50 | 72.80 | Par |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 224.38M | 3.66B | Emerging |
